局部复发前列腺癌的挽救性再照射:一项随访7.2年的前瞻性研究结果
这项前瞻性研究纳入38例根治性放疗后局部复发的前列腺癌患者,采用35 Gy分5次的外照射放疗,并在放疗前3个月开始为期6个月的雄激素剥夺治疗。中位随访7.2年,5年生化复发无生存率为58%,晚期3级泌尿生殖毒性发生率为5%。
要点
- 35 Gy分5次再照射联合6个月雄激素剥夺治疗,5年生化复发无生存率为58%。
- 5年局部复发无生存率为93%,无转移生存率为82%,总生存率为87%。
- 5%的患者出现持续性3级泌尿生殖毒性,其中1例合并3级胃肠道毒性。
核心结论
- 对于根治性放疗后局部复发的前列腺癌,外照射再照射在临床上是可行的,在这项长期随访的前瞻性研究中显示出良好的结局和可接受的毒性。
研究设计与样本
- 2013年至2017年前瞻性纳入38例经活检证实局部复发、距前次治疗超过2年且首程放疗无2-3级毒性的前列腺癌患者。
- 治疗方案为基于MRI靶区的35 Gy分5次照射,并联合6个月雄激素剥夺治疗,自放疗前3个月开始。
- 生化复发无生存采用Phoenix标准定义,毒性按放射治疗肿瘤学组标准评分。
主要发现
- 中位年龄70岁,从初次放疗至前列腺特异性抗原(PSA)复发的中位时间为83个月。
- 2年和5年生化复发无生存率分别为81%(95%CI,69至94)和58%(95%CI,49至74)。
- 5年局部复发无生存率为93%(95%CI,82至100),无转移生存率为82%(95%CI,69至95),总生存率为87%(95%CI,76至98)。
- 2例患者(5%)出现持续性3级泌尿生殖毒性,其中1例合并3级胃肠道毒性。
- 挽救治疗时PSA倍增时间≤6个月、Gleason评分>7和PSA最低值≥0.1 ng/mL预示更差的结局。
关键数值与推荐
- 再照射剂量为35 Gy分5次,雄激素剥夺治疗持续6个月,自放疗前3个月开始。
- 生化复发无生存采用Phoenix标准定义,毒性按放射治疗肿瘤学组标准评分。
临床怎么用
- 作者认为,对于根治性放疗后局部复发的前列腺癌,外照射再照射在临床上是可行的,并显示出良好的结局和可接受的毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are no well-established re-treatment options for local recurrence after primary curative radiation therapy for prostate cancer (PCa), as prospective studies with long-term follow-up are lacking. Here, we present results from a prospective study on focal salvage reirradiation with external-beam radiation therapy with a median follow-up of 7.2 years. MATERIALS AND METHODS: From 2013 to 2017, 38 patients with biopsy-proven locally recurrent PCa >2 years after previous treatment and absence of grade 2-3 toxicity from the first course of radiation were included. The treatment was 35 Gy in five fractions to the MRI-based target volume and 6 months of androgen-deprivation therapy starting 3 months before radiation. The Phoenix criteria defined biochemical recurrence-free survival (bRFS), and toxicity was scored according to Radiation Therapy Oncology Group criteria. RESULTS: Median age was 70 years, and median time from primary radiation to prostate-specific antigen (PSA) recurrence was 83 months. The actuarial 2-year and 5-year bRFS were 81% (95% CI, 69 to 94) and 58% (95% CI, 49 to 74), respectively. The actuarial 5-year local recurrence-free survival was 93% (95% CI, 82 to 100), metastasis-free survival was 82% (95% CI, 69 to 95), and overall survival was 87% (95% CI, 76 to 98). Two patients (5%) had durable grade 3 genitourinary toxicity, one combined with GI grade 3 toxicity. A PSA doubling time ≤6 months at salvage, a Gleason score >7, and a PSA nadir ≥0.1 ng/mL predicted a worse outcome. CONCLUSION: Reirradiation with EBRT for locally recurrent PCa after primary curative radiation therapy is clinically feasible and demonstrated a favorable outcome with acceptable toxicity in this prospective study with long-term follow-up.
引用
- Ekanger C, Helle SI, Reisæter L, et al. Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up. J Clin Oncol. 2024. PMID: 38652872. doi:10.1200/JCO.23.01391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。